Discovery, Characterization, and Manufacture of Peptide Radiopharmaceuticals

A new wave of drugs that achieves targeted delivery of radioisotopes is rapidly gaining momentum.  As the discovery pipeline widens and new drug approvals increase, the field is expanding and becoming more diverse in the strategies employed to deliver cell-killing radioisotopes.

One area that is showing considerable promise is the incorporation of an isotope-chelating moiety into a peptide ligand for targeting cell surface receptors on cancer cells. In this webinar, we discuss strategies for the discovery and optimization of new peptide ligands for such targets, as well as their synthesis, efficacy, metabolism/distribution, and manufacture.

Read our expert answers to frequently asked questions from this webinar: FAQs